CA2803005A1 - Synthesis and use of kinase inhibitors - Google Patents

Synthesis and use of kinase inhibitors Download PDF

Info

Publication number
CA2803005A1
CA2803005A1 CA2803005A CA2803005A CA2803005A1 CA 2803005 A1 CA2803005 A1 CA 2803005A1 CA 2803005 A CA2803005 A CA 2803005A CA 2803005 A CA2803005 A CA 2803005A CA 2803005 A1 CA2803005 A1 CA 2803005A1
Authority
CA
Canada
Prior art keywords
compound
formula
solvent
aryl
free base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2803005A
Other languages
English (en)
French (fr)
Inventor
Yixiong Lei
Carl Henry Behrens
Hui-Yin Li
Connie L. Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Poniard Pharmaceuticals Inc
Original Assignee
Poniard Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poniard Pharmaceuticals Inc filed Critical Poniard Pharmaceuticals Inc
Publication of CA2803005A1 publication Critical patent/CA2803005A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CA2803005A 2010-06-30 2011-06-28 Synthesis and use of kinase inhibitors Abandoned CA2803005A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35994210P 2010-06-30 2010-06-30
US61/359,942 2010-06-30
PCT/US2011/042169 WO2012012139A1 (en) 2010-06-30 2011-06-28 Synthesis and use of kinase inhibitors

Publications (1)

Publication Number Publication Date
CA2803005A1 true CA2803005A1 (en) 2012-01-26

Family

ID=45497129

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2803005A Abandoned CA2803005A1 (en) 2010-06-30 2011-06-28 Synthesis and use of kinase inhibitors

Country Status (10)

Country Link
US (1) US9505719B2 (https=)
EP (1) EP2588476A4 (https=)
JP (1) JP5923499B2 (https=)
CN (1) CN103168037A (https=)
AU (1) AU2011280031B2 (https=)
CA (1) CA2803005A1 (https=)
MX (1) MX343894B (https=)
NZ (1) NZ604801A (https=)
WO (1) WO2012012139A1 (https=)
ZA (1) ZA201300012B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2675793B1 (en) 2011-02-17 2018-08-08 Cancer Therapeutics Crc Pty Limited Fak inhibitors
JP5937112B2 (ja) 2011-02-17 2016-06-22 カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドＣａｎｃｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｒｃ Ｐｔｙ Ｌｉｍｉｔｅｄ 選択的ｆａｋ阻害剤
WO2019117813A1 (en) * 2017-12-15 2019-06-20 National University Of Singapore Focal adhesion kinase targeted therapeutics for the treatment of glaucoma and fibrosis

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656182A (en) * 1983-12-06 1987-04-07 Warner-Lambert Company Substituted trans-1,2-diaminocyclohexyl amide compounds
US20040006005A1 (en) 2002-07-02 2004-01-08 Sanjay Bhanot Use of integrin-linked kinase inhibitors for treating insulin resistance, hyperglycemia and diabetes
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
BR0114814A (pt) 2000-10-11 2005-01-25 Cephalon Inc Composições compreendendo composto de modafinila e seu uso
AR040456A1 (es) * 2002-06-27 2005-04-06 Bristol Myers Squibb Co Piridina n-oxidos 2,4 -disubstituidos utiles como inhibidores de transcriptasa inversa del virus de inmunodeficiencia humana
US20080119515A1 (en) 2003-03-10 2008-05-22 M Arshad Siddiqui Heterocyclic Kinase Inhibitors: Methods of Use and Synthesis
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos
ES2533258T3 (es) 2005-02-18 2015-04-08 Janssen Sciences Ireland Uc Derivados de óxido de 2-(4-cianofenilamino)pirimidina que inhiben el VIH
WO2007050574A1 (en) 2005-10-25 2007-05-03 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
EP2012753A2 (en) * 2006-04-28 2009-01-14 Schering Corporation Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0]hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
CN101495095B (zh) * 2006-04-28 2013-05-29 默沙东公司 通过受控的沉淀来沉淀和分离6,6-二甲基-3-氮杂-双环[3.1.0]己烷-酰胺化合物的方法和含有其的药学制剂
EP2046292B1 (en) 2006-07-21 2010-03-03 Novartis AG Formulations for benzimidazolyl pyridyl ethers
DK2134689T3 (da) * 2007-03-16 2014-06-30 Scripps Research Inst Inhibitorer af fokal adhæsionskinase
WO2009100176A2 (en) 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
WO2009105498A1 (en) * 2008-02-19 2009-08-27 Smithkline Beecham Corporation Anilinopyridines as inhibitors of fak
MX2010014057A (es) * 2008-06-17 2011-03-21 Astrazeneca Ab Compuestos de piridina.
CN102648197A (zh) 2009-08-12 2012-08-22 铂雅制药公司 促进细胞凋亡和抑制转移的方法
WO2011133668A2 (en) 2010-04-20 2011-10-27 President And Fellows Of Harvard College Methods and compositions for the treatment of cancer

Also Published As

Publication number Publication date
US20140235635A1 (en) 2014-08-21
JP5923499B2 (ja) 2016-05-24
ZA201300012B (en) 2013-09-25
MX343894B (es) 2016-11-28
AU2011280031B2 (en) 2015-09-10
AU2011280031A1 (en) 2013-01-10
MX2012014986A (es) 2013-07-03
US9505719B2 (en) 2016-11-29
EP2588476A4 (en) 2014-07-23
NZ604801A (en) 2015-03-27
EP2588476A1 (en) 2013-05-08
JP2013529687A (ja) 2013-07-22
CN103168037A (zh) 2013-06-19
WO2012012139A1 (en) 2012-01-26

Similar Documents

Publication Publication Date Title
ES2487215T3 (es) Proceso mejorado
US20170355679A1 (en) Fluorinated 2-amino-4-(substituted amino)phenyl carbamate derivatives
CN104961672A (zh) 一种n-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n’-(4-异丁氧基苄基)脲的酒石酸盐的合成方法
CA2772080C (en) Synthesis of a neurostimulative piperazine
DE2623447A1 (de) N-substituierte 2-methoxy-benzolsulfonamide, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
CA2803005A1 (en) Synthesis and use of kinase inhibitors
CN102076679A (zh) 新颖的四甲基取代的哌啶衍生物及其作为单胺神经递质再摄取抑制剂的用途
CN104744558B (zh) 柠檬苦素‑7‑氨基衍生物、其制法以及医药用途
ES2201105T3 (es) Derivados del bencimidazol con actividad dopaminergica.
ES2916406T3 (es) Procedimiento continuo para la preparación de trazodona
CN111574533B (zh) 柠檬苦素a环开环胺化衍生物或其药学上可接受的盐、制备方法及用途
ZA200608856B (en) Crystalline forms of N-desmethylclozapine
SG188472A1 (en) Prodrugs of guanfacine
JPS6043348B2 (ja) 新規化合物またはその生理的に許容可能な塩及びこれらの製造法
CN107216271B (zh) 酒石酸匹莫范色林杂质及其制备方法
CN112574061B (zh) 一种trpv1激动剂及其制备方法和用途
CN119613419A (zh) 氘代的二芳基甘脲四聚体化合物及其用途
CH643256A5 (de) 4-oxo-4h-pyrido(1,2-a)pyrimidin-3-n(1h-tetrazol-5-yl)-carboxamide und verfahren zu ihrer herstellung.
ES2520021T3 (es) Derivados de 3,4-diamino-3-ciclobuteno-1,2-diona como aperturas de canal de potasio
CN102936244B (zh) 一种他克林-吩噻嗪异二联体类化合物及其制备方法
JP7818600B2 (ja) Ｅｎｐｐ１阻害剤としてのイミダゾール化合物
CN115768774B (zh) 氘代四氢噻吩并[3,4-d]嘧啶二酮化合物以及包含该化合物的药物组合物
US3096335A (en) Lower alkyl 1-(phenylaminoalkyl)-4-phenyl-4-piperidyl ketones
KR101868438B1 (ko) 아미드 유도체의 제조방법
ES2336384T3 (es) Nuevas dihidropirazinas triciclicas como elementos de apertura del apertura del canal de potasio.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160615

FZDE Dead

Effective date: 20190211